# Immunome Inc.: overview

IMNM · Nasdaq · CIK 1472012 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/imnm.md) · [Financials](/companies/imnm/financials.md) · [Filings](/companies/imnm/filings.md) · [Insiders](/companies/imnm/insiders.md)

Latest reported revenue: [$0](/filings/0001193125-26-344636.md) for Q2 FY2026, three months to 2026-06-30, from the 10-Q filed Aug 11, 2026 (XBRL us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax, accession 0001193125-26-344636).

## Last eight quarters

| Line item | Unit | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [2.9](/filings/0001193125-25-269603.md) | [2.7 d](/filings/0001193125-26-088172.md) | [2.9](/filings/0001193125-26-219425.md) | [4.0](/filings/0001193125-26-344636.md) | [0.0](/filings/0001193125-25-269603.md) | [0.0 d](/filings/0001193125-26-088172.md) | [0.0](/filings/0001193125-26-219425.md) | [0.0](/filings/0001193125-26-344636.md) |
| Gross margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Operating margin | % | [(1736.2%)](/filings/0001193125-25-269603.md) | [(3030.3%) d](/filings/0001193125-26-088172.md) | [(1525.5%)](/filings/0001193125-26-219425.md) | [(1157.6%)](/filings/0001193125-26-344636.md) | not reported | not reported | not reported | not reported |
| Net margin | % | [(1618.6%)](/filings/0001193125-25-269603.md) | [(2930.9%) d](/filings/0001193125-26-088172.md) | [(1423.1%)](/filings/0001193125-26-344636.md) | [(1080.9%)](/filings/0001193125-26-344636.md) | not reported | not reported | not reported | not reported |
| Diluted EPS | $ per share | [(0.78)](/filings/0001193125-25-269603.md) | not reported | [(0.52)](/filings/0001193125-26-219425.md) | [(0.50)](/filings/0001193125-26-344636.md) | [(0.65)](/filings/0001193125-25-269603.md) | not reported | [(0.48)](/filings/0001193125-26-219425.md) | [(0.65)](/filings/0001193125-26-344636.md) |
| Free cash flow | $m | [(35.7) d](/filings/0001193125-25-269603.md) | [(43.2) d](/filings/0001193125-26-088172.md) | [(56.7)](/filings/0001193125-26-219425.md) | [(50.3) d](/filings/0001193125-26-344636.md) | [(41.6) d](/filings/0001193125-25-269603.md) | [(52.0) d](/filings/0001193125-26-088172.md) | [(61.6)](/filings/0001193125-26-219425.md) | [(63.9) d](/filings/0001193125-26-344636.md) |

- Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure.

## Last five fiscal years

| Line item | Unit | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | not reported | not reported | [14.0](/filings/0001558370-25-003302.md) | [9.0](/filings/0001193125-26-088172.md) | [6.9](/filings/0001193125-26-088172.md) |
| Gross margin | % | not reported | not reported | not reported | not reported | not reported |
| Operating margin | % | not reported | not reported | [(781.4%)](/filings/0001558370-25-003302.md) | [(3382.4%)](/filings/0001193125-26-088172.md) | [(3228.8%)](/filings/0001193125-26-088172.md) |
| Net margin | % | not reported | not reported | [(761.9%)](/filings/0001558370-25-003302.md) | [(3240.4%)](/filings/0001193125-26-088172.md) | [(3060.0%)](/filings/0001193125-26-088172.md) |
| Diluted EPS | $ per share | [(2.14)](/filings/0001558370-23-003964.md) | [(3.09)](/filings/0001558370-24-004247.md) | [(5.38)](/filings/0001558370-25-003302.md) | [(5.00)](/filings/0001193125-26-088172.md) | [(2.43)](/filings/0001193125-26-088172.md) |
| Free cash flow | $m | [(18.3)](/filings/0001558370-23-003964.md) | [(28.9)](/filings/0001558370-24-004247.md) | [(8.4)](/filings/0001558370-25-003302.md) | [(118)](/filings/0001193125-26-088172.md) | [(201)](/filings/0001193125-26-088172.md) |

- Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment.

Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing.

## Insider purchases and sales

The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/imnm/insiders.md)

None in coverage.

## Funds that report holding it

From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md)

| Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before |
| --- | --- | ---: | ---: | --- | --- |
| [FMR LLC](/funds/315066.md) | 2026-06-30 | $360.0m | 16,987,553 |  | Added +17,599 |
| [BlackRock, Inc.](/funds/2012383.md) | 2026-06-30 | $186.6m | 8,805,492 |  | Added +636,818 |
| [STATE STREET CORP](/funds/93751.md) | 2026-06-30 | $116.4m | 5,494,625 |  | Added +94,724 |
| [WELLINGTON MANAGEMENT GROUP LLP](/funds/902219.md) | 2026-06-30 | $110.4m | 5,210,216 |  | Added +478,239 |
| [Redmile Group, LLC](/funds/1425738.md) | 2026-06-30 | $104.1m | 4,911,590 |  | Reduced −647,295 |
| [PRIMECAP MANAGEMENT CO/CA/](/funds/763212.md) | 2026-06-30 | $97.1m | 4,581,431 |  | Reduced −206,800 |
| [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $96.4m | 4,551,289 |  | Added +121,592 |
| [Driehaus Capital Management LLC](/funds/938206.md) | 2026-06-30 | $92.1m | 4,346,139 |  | Added +246,238 |
| [ENAVATE SCIENCES GP, LLC](/funds/1953107.md) | 2026-06-30 | $76.6m | 3,613,799 |  | Unchanged |
| [GEODE CAPITAL MANAGEMENT, LLC](/funds/1214717.md) | 2026-06-30 | $58.4m | 2,754,889 |  | Added +194,225 |

## Recent filings

[All 457 filings](/companies/imnm/filings.md)

| Filed | Accepted | Form | What it is | Accession |
| --- | --- | --- | --- | --- |
| 2026-10-05 | 08:30 ET | [8-K](/filings/0001193125-26-413217.md) | 1.01 Entry into a material agreement; 3.02 Unregistered sale of equity; 9.01 Financial statements and exhibits | 0001193125-26-413217 |
| 2026-08-11 | 16:10 ET | [10-Q](/filings/0001193125-26-344636.md) | Quarterly report, period 2026-06-30 | 0001193125-26-344636 |
| 2026-08-11 | 16:05 ET | [8-K](/filings/0001193125-26-344577.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-26-344577 |
| 2026-06-12 | 16:05 ET | [8-K](/filings/0001193125-26-269383.md) | 5.07 Shareholder vote results | 0001193125-26-269383 |
| 2026-05-12 | 16:10 ET | [10-Q](/filings/0001193125-26-219425.md) | Quarterly report, period 2026-03-31 | 0001193125-26-219425 |
| 2026-05-12 | 16:05 ET | [8-K](/filings/0001193125-26-219367.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-26-219367 |
| 2026-04-24 | 16:05 ET | [DEF 14A](/filings/0001140361-26-016685.md) | Proxy statement, period 2026-06-09 | 0001140361-26-016685 |
| 2026-03-03 | 16:07 ET | [10-K](/filings/0001193125-26-088172.md) | Annual report, period 2025-12-31 | 0001193125-26-088172 |
| 2026-03-03 | 16:05 ET | [8-K](/filings/0001193125-26-088141.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-26-088141 |
| 2025-12-22 | 21:22 ET | [SCHEDULE 13D/A](/filings/0001953107-25-000019.md) | Ownership report, active investor, amended | 0001953107-25-000019 |

## Latest annual report

[Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001193125-26-088172.md), filed Mar 3, 2026.

## Forecast league

Q3 FY2026, the quarter ended 2026-09-30, is open for forecasts until the first results filing for it is accepted by EDGAR. Results are due by \[object Promise\]. [Forecast this quarter](/leagues/2026q3/targets/85f46e0e-c61c-4641-9d13-f21f7d826ef1)

## About the filer

- CIK: 1472012
- Tickers: IMNM
- Exchange: Nasdaq
- SIC code: 2834 Pharmaceutical Preparations
- State of incorporation: DE
- Filer category: Non-accelerated filer

Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 30, 2026, 12:06 ET. No prices; not investment advice.